Free Trial

Cullinan Therapeutics (CGEM) Competitors

Cullinan Therapeutics logo
$6.62 +0.15 (+2.32%)
Closing price 09/11/2025 04:00 PM Eastern
Extended Trading
$6.52 -0.10 (-1.57%)
As of 08:09 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CGEM vs. SRPT, MESO, APGE, CDTX, BEAM, BHVN, TWST, IMCR, AUPH, and TVTX

Should you be buying Cullinan Therapeutics stock or one of its competitors? The main competitors of Cullinan Therapeutics include Sarepta Therapeutics (SRPT), Mesoblast (MESO), Apogee Therapeutics (APGE), Cidara Therapeutics (CDTX), Beam Therapeutics (BEAM), Biohaven (BHVN), Twist Bioscience (TWST), Immunocore (IMCR), Aurinia Pharmaceuticals (AUPH), and Travere Therapeutics (TVTX). These companies are all part of the "pharmaceutical products" industry.

Cullinan Therapeutics vs. Its Competitors

Cullinan Therapeutics (NASDAQ:CGEM) and Sarepta Therapeutics (NASDAQ:SRPT) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and dividends.

Cullinan Therapeutics presently has a consensus price target of $27.67, suggesting a potential upside of 317.93%. Sarepta Therapeutics has a consensus price target of $42.36, suggesting a potential upside of 136.52%. Given Cullinan Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Cullinan Therapeutics is more favorable than Sarepta Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cullinan Therapeutics
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
3.00
Sarepta Therapeutics
6 Sell rating(s)
15 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.07

Cullinan Therapeutics has a beta of -0.08, indicating that its share price is 108% less volatile than the S&P 500. Comparatively, Sarepta Therapeutics has a beta of 0.49, indicating that its share price is 51% less volatile than the S&P 500.

86.3% of Cullinan Therapeutics shares are held by institutional investors. Comparatively, 86.7% of Sarepta Therapeutics shares are held by institutional investors. 7.2% of Cullinan Therapeutics shares are held by company insiders. Comparatively, 7.6% of Sarepta Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Cullinan Therapeutics has a net margin of 0.00% compared to Sarepta Therapeutics' net margin of -2.34%. Sarepta Therapeutics' return on equity of -1.03% beat Cullinan Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Cullinan TherapeuticsN/A -36.56% -34.82%
Sarepta Therapeutics -2.34%-1.03%-0.37%

In the previous week, Sarepta Therapeutics had 13 more articles in the media than Cullinan Therapeutics. MarketBeat recorded 22 mentions for Sarepta Therapeutics and 9 mentions for Cullinan Therapeutics. Sarepta Therapeutics' average media sentiment score of 1.13 beat Cullinan Therapeutics' score of 1.01 indicating that Sarepta Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cullinan Therapeutics
3 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Sarepta Therapeutics
9 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Sarepta Therapeutics has higher revenue and earnings than Cullinan Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cullinan TherapeuticsN/AN/A-$167.38M-$3.23-2.05
Sarepta Therapeutics$2.48B0.71$235.24M-$0.87-20.59

Summary

Sarepta Therapeutics beats Cullinan Therapeutics on 11 of the 15 factors compared between the two stocks.

Get Cullinan Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CGEM and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CGEM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CGEM vs. The Competition

MetricCullinan TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$382.21M$3.15B$5.78B$10.07B
Dividend YieldN/A2.32%5.69%4.62%
P/E Ratio-2.0521.6075.0426.20
Price / SalesN/A297.80469.7391.86
Price / CashN/A45.3337.0859.91
Price / Book0.659.7112.236.28
Net Income-$167.38M-$53.33M$3.29B$270.85M
7 Day Performance-5.29%1.04%1.53%3.58%
1 Month Performance-8.94%9.93%7.86%6.67%
1 Year Performance-62.43%13.80%63.05%27.74%

Cullinan Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CGEM
Cullinan Therapeutics
2.4688 of 5 stars
$6.62
+2.3%
$27.67
+317.9%
-63.2%$382.21MN/A-2.0530News Coverage
Positive News
Analyst Forecast
High Trading Volume
SRPT
Sarepta Therapeutics
4.4678 of 5 stars
$18.20
-0.8%
$43.50
+139.0%
-86.1%$1.78B$1.90B-20.921,372Trending News
Analyst Forecast
Analyst Revision
High Trading Volume
MESO
Mesoblast
1.5968 of 5 stars
$13.83
-13.3%
$18.00
+30.2%
+148.7%$1.77B$5.90M0.0080High Trading Volume
APGE
Apogee Therapeutics
2.9298 of 5 stars
$36.37
-0.7%
$97.29
+167.5%
-26.4%$1.68BN/A-8.8191News Coverage
Positive News
CDTX
Cidara Therapeutics
3.3128 of 5 stars
$65.39
+0.2%
$64.14
-1.9%
+458.3%$1.66B$1.27M-5.8890Positive News
BEAM
Beam Therapeutics
3.0504 of 5 stars
$16.36
-2.9%
$48.45
+196.2%
-10.7%$1.66B$63.52M-3.64510
BHVN
Biohaven
3.3012 of 5 stars
$15.35
-1.1%
$54.23
+253.2%
-60.4%$1.63BN/A-2.00239Trending News
TWST
Twist Bioscience
4.0011 of 5 stars
$26.97
+1.4%
$49.40
+83.2%
-42.3%$1.63B$312.97M-18.60990News Coverage
IMCR
Immunocore
1.8692 of 5 stars
$32.22
-0.1%
$56.89
+76.6%
+10.9%$1.62B$310.20M-80.55320
AUPH
Aurinia Pharmaceuticals
2.9892 of 5 stars
$11.99
-0.7%
$12.00
+0.1%
+95.7%$1.58B$235.13M27.88300Positive News
TVTX
Travere Therapeutics
3.0091 of 5 stars
$17.50
-1.1%
$33.43
+91.0%
+104.2%$1.56B$233.18M-8.58460Trending News
Analyst Forecast

Related Companies and Tools


This page (NASDAQ:CGEM) was last updated on 9/12/2025 by MarketBeat.com Staff
From Our Partners